Angela L. McCleary‐Wheeler

Closest collaborators

The 25 strongest of 34 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Martín E. Fernández-Zapico · 4 shared papers, 2012–2020 · strength 0.25
   • Paper Targeting of the Hedgehog/GLI and mTOR pathways in advanced pancreatic cancer, a phase 1 trial of Vismodegib and Siroli… DOI 10.1016/j.pan.2020.06.015↗
   • Paper Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer. DOI 10.1016/j.pan.2019.11.011↗
   • Paper Aberrant signaling pathways in pancreatic cancer: a two compartment view. DOI 10.1002/mc.20827↗
2. Mitesh J. Borad · 2 shared papers, 2020 · strength 0.16
   • Paper Targeting of the Hedgehog/GLI and mTOR pathways in advanced pancreatic cancer, a phase 1 trial of Vismodegib and Siroli… DOI 10.1016/j.pan.2020.06.015↗
   • Paper Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer. DOI 10.1016/j.pan.2019.11.011↗
3. Thomas C. Smyrk · 2 shared papers, 2020 · strength 0.16
   • Paper Targeting of the Hedgehog/GLI and mTOR pathways in advanced pancreatic cancer, a phase 1 trial of Vismodegib and Siroli… DOI 10.1016/j.pan.2020.06.015↗
   • Paper Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer. DOI 10.1016/j.pan.2019.11.011↗
4. Ryan Michael Carr · 2 shared papers, 2020 · strength 0.16
   • Paper Targeting of the Hedgehog/GLI and mTOR pathways in advanced pancreatic cancer, a phase 1 trial of Vismodegib and Siroli… DOI 10.1016/j.pan.2020.06.015↗
   • Paper Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer. DOI 10.1016/j.pan.2019.11.011↗
5. Charles Erlichman · 2 shared papers, 2020 · strength 0.16
   • Paper Targeting of the Hedgehog/GLI and mTOR pathways in advanced pancreatic cancer, a phase 1 trial of Vismodegib and Siroli… DOI 10.1016/j.pan.2020.06.015↗
   • Paper Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer. DOI 10.1016/j.pan.2019.11.011↗
6. Tanios Bekaii‐Saab · 2 shared papers, 2020 · strength 0.16
   • Paper Targeting of the Hedgehog/GLI and mTOR pathways in advanced pancreatic cancer, a phase 1 trial of Vismodegib and Siroli… DOI 10.1016/j.pan.2020.06.015↗
   • Paper Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer. DOI 10.1016/j.pan.2019.11.011↗
7. Robert R. McWilliams · 2 shared papers, 2012–2020 · strength 0.13
   • Paper Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer. DOI 10.1016/j.pan.2019.11.011↗
   • Paper Aberrant signaling pathways in pancreatic cancer: a two compartment view. DOI 10.1002/mc.20827↗
8. Aminah Jatoi · 2 shared papers, 2015–2020 · strength 0.11
   • Paper Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer. DOI 10.1016/j.pan.2019.11.011↗
   • Paper A preoperative serum signature of CEA+/CA125+/CA19-9 ≥ 1000 U/mL indicates poor outcome to pancreatectomy for pancreati… DOI 10.1002/ijc.29242↗
9. Alex A. Adjei · 1 shared paper, 2020 · strength 0.09
   • Paper Targeting of the Hedgehog/GLI and mTOR pathways in advanced pancreatic cancer, a phase 1 trial of Vismodegib and Siroli… DOI 10.1016/j.pan.2020.06.015↗
10. Rondell Patrell Graham · 1 shared paper, 2020 · strength 0.09
    • Paper Targeting of the Hedgehog/GLI and mTOR pathways in advanced pancreatic cancer, a phase 1 trial of Vismodegib and Siroli… DOI 10.1016/j.pan.2020.06.015↗
11. George Kim · 1 shared paper, 2020 · strength 0.09
    • Paper Targeting of the Hedgehog/GLI and mTOR pathways in advanced pancreatic cancer, a phase 1 trial of Vismodegib and Siroli… DOI 10.1016/j.pan.2020.06.015↗
12. Wilma Lingle · 1 shared paper, 2020 · strength 0.08
    • Paper Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer. DOI 10.1016/j.pan.2019.11.011↗
13. Ezequiel J. Tolosa · 1 shared paper, 2020 · strength 0.08
    • Paper Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer. DOI 10.1016/j.pan.2019.11.011↗
14. Axel F. Grothey · 1 shared paper, 2020 · strength 0.08
    • Paper Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer. DOI 10.1016/j.pan.2019.11.011↗
15. Julian R. Molina · 1 shared paper, 2020 · strength 0.08
    • Paper Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer. DOI 10.1016/j.pan.2019.11.011↗
16. Henry Clement Pitot · 1 shared paper, 2020 · strength 0.08
    • Paper Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer. DOI 10.1016/j.pan.2019.11.011↗
17. George P. Kim · 1 shared paper, 2020 · strength 0.08
    • Paper Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer. DOI 10.1016/j.pan.2019.11.011↗
18. Mien‐Chie Hung · 1 shared paper, 2020 · strength 0.08
    • Paper Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer. DOI 10.1016/j.pan.2019.11.011↗
19. Quanxing Ni · 1 shared paper, 2015 · strength 0.04
    • Paper A preoperative serum signature of CEA+/CA125+/CA19-9 ≥ 1000 U/mL indicates poor outcome to pancreatectomy for pancreati… DOI 10.1002/ijc.29242↗
20. Jin Xu · 1 shared paper, 2015 · strength 0.04
    • Paper A preoperative serum signature of CEA+/CA125+/CA19-9 ≥ 1000 U/mL indicates poor outcome to pancreatectomy for pancreati… DOI 10.1002/ijc.29242↗
21. Min Li · 1 shared paper, 2015 · strength 0.04
    • Paper A preoperative serum signature of CEA+/CA125+/CA19-9 ≥ 1000 U/mL indicates poor outcome to pancreatectomy for pancreati… DOI 10.1002/ijc.29242↗
22. Huaxiang Xu · 1 shared paper, 2015 · strength 0.04
    • Paper A preoperative serum signature of CEA+/CA125+/CA19-9 ≥ 1000 U/mL indicates poor outcome to pancreatectomy for pancreati… DOI 10.1002/ijc.29242↗
23. Wenquan Wang · 1 shared paper, 2015 · strength 0.04
    • Paper A preoperative serum signature of CEA+/CA125+/CA19-9 ≥ 1000 U/mL indicates poor outcome to pancreatectomy for pancreati… DOI 10.1002/ijc.29242↗
24. Jiang Long · 1 shared paper, 2015 · strength 0.04
    • Paper A preoperative serum signature of CEA+/CA125+/CA19-9 ≥ 1000 U/mL indicates poor outcome to pancreatectomy for pancreati… DOI 10.1002/ijc.29242↗
25. Liang Liu · 1 shared paper, 2015 · strength 0.04
    • Paper A preoperative serum signature of CEA+/CA125+/CA19-9 ≥ 1000 U/mL indicates poor outcome to pancreatectomy for pancreati… DOI 10.1002/ijc.29242↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.